Tag Archives: HIV

Potent antibodies neutralize HIV and could offer new therapy, study finds

Rockefeller researchers in Michel Nussenzweig’s Laboratory of Molecular Immunology have found that a newly-discovered class of especially potent antibodies is effective at neutralizing HIV infection in mice for a 60 day period, longer than current antiretroviral drugs which require daily application. The antibodies, which suppressed the virus when used in combination, could one day be given to humans to treat the disease. More »

Tags: , , ,

Johannes Scheid wins 2012 Weintraub Graduate Student Award

Scheid is one of 13 awardees, all advanced graduate students at or near the completion of their studies in the biological sciences and chosen for the quality, originality and significance of their thesis research.
More »

Tags: ,

Research on killer HIV antibodies provides promising new ideas for vaccine design

By detailing the molecular workings of broadly neutralizing anti-HIV antibodies, found in so-called slow-progressing HIV patients, researchers hope to devise a way to arm those who are not equipped with exceptional immunological firepower. New clues reveal that some anti-HIV antibodies are especially sticky and target a previously unrecognized part of the virus. More »

Tags: , ,

Immune system uses a “leash” to restrict HIV’s spread

New research shows how an antiviral protein, tetherin, lashes newborn viral particles to infected cells, slowing the spread of infection. Understanding how this immune system defense works against HIV, Ebola and other deadly viruses could lead to better antiviral therapies. More »

Tags: , ,

A natural approach for HIV vaccine

Since HIV was first recognized in the early 1980s, scientists have tried and failed to develop a vaccine based on a handful of “super antibodies” that so far have been impossible to produce in humans. Now new research detailing the dynamic, natural immune response in “slow-progressing” HIV patients suggests that an effective HIV vaccine may come from a shotgun approach targeting several parts of the virus rather than a magic bullet targeting only one. More »

Tags: ,

Researchers unveil new monkey model for HIV

For the first time, scientists have succeeded in engineering a strain of HIV-1 that they can study in monkeys. Just one gene different from the deadly retrovirus that works all too well in humans, the new strain spreads in pig-tailed macaques almost as ferociously as it does in humans. Researchers at The Rockefeller University have already used it to demonstrate one method for preventing HIV-1 infection. With some minor changes, it could become a valuable model for vetting vaccine candidates. More »

Tags: ,

Scientists image a single HIV particle being born

For some, the saying “seeing is believing” has taken on a new meaning. In research to be published in the May 25 advance online issue of Nature, scientists at Rockefeller University and the Aaron Diamond AIDS Research Center have become the first to see, in real time and in plain sight, an HIV particle being born. The images, created using a technique that illuminates only the surface of the cell, where the virus assembles, have the potential to help researchers develop new treatments for AIDS. More »

Tags: , ,

Understanding primate evolution could aid HIV research

The discovery of an evolutionary duplication — the same genetic mutation in two species of monkey — is providing researchers with new insight into evolution and a potential new subject for an animal model for HIV. More »

Tags: ,

Experimental HIV vaccine gets a boost from ’70s-era discovery

A long-neglected molecule called poly-IC may see new life as a vaccine adjuvant. New research shows that, in combination with a novel AIDS vaccine, it helps mice maintain their immunity. More »

Tags: ,

Protein discovered that prevents HIV from spreading

In a study that could open up a new area of virology, scientists have found a molecule that keeps mutant strains of HIV from leaving their host cell. This new protein, tetherin, causes new virus particles to stay stuck to the outer membrane and be reabsorbed by the cell. More »

Tags: , ,

Analysis of Chinese AIDs epidemic shows surprising patterns

The Chinese province of Yunnan was the country’s point of entry for HIV, and is the area in which the AIDS epidemic is most widespread. The viral mutations that exist in Yunnan are far more diverse than anywhere else in the country, and recent research suggests that HIV in China may be spread by sexual contact more quickly than anyone believed. The result: a new subtype of the virus that has the potential to jumpstart a new epidemic. More »

Tags: ,

Dendritic cell receptor may be the key to an HIV vaccine

Recent attempts to develop a vaccine have elicited only limited action from two immune system cells, helper T cells and killer T cells. But Rockefeller University scientists working on a new approach have evidence that targeting a third group of immune cells, dendritic cells, may be even more effective than they’d previously believed. Now new research shows that the dendritic cells’ DEC-205 receptor may be the key to making it work. More »

Tags: , ,

Viral detectives: Researchers track down the location of HIV-1 assembly in human cells

New research by Rockefeller University and ADARC scientists pinpoints the location of HIV-1 assembly in human immune cells. Although the assembly site had long been a topic of dispute, the researchers show conclusively that the virus is being built in the cells’ plasma membranes and not, as many had supposed, in internal cellular compartments called endosomes. More »

Tags: , , ,

HIV-1 kills immune cells in the gut that may never bounce back

People with HIV have been living longer, healthier lives since the development of highly active antiretroviral therapy (or HAART) in 1995. In fact, most patients on the drug regimen do so well that, according to blood tests, their immune cells appear to return to pre-HIV levels. But two new studies from Rockefeller University and the Aaron Diamond AIDS Research Center show that within the gastrointestinal tract, recovery of immune cells is incomplete despite years of prolonged treatment, suggesting the need for additional ways to monitor immune system health, and the need for hypervigilance as HIV-positive patients live into their forties, fifties, sixties and beyond. More »

Tags: ,

HIV gets a makeover: A few adjustments to the AIDS virus could alter the course of research

In an advance that has the potential to revolutionize AIDS vaccine research, researchers at Rockefeller University and the Aaron Diamond AIDS Research Center have used a combination of genetic engineering and forced adaptation to create a version of HIV that replicates vigorously in human and monkey cells. More »

Tags: ,

HIV protein acts as a solvent, releasing viral particles from the surface of their host cell

In the 17 years since the Vpu protein was shown to help HIV spread between cells, no clear theory has emerged to explain exactly how it works. But now, scientists at the Aaron Diamond AIDS Research Center (ADARC) and Rockefeller University have uncovered a very specific role for Vpu: It works like a solvent to “unstick” viruses from the membrane of the cell that produced them, allowing them to be released and spread to adjacent cells. More »

Tags: , ,

By targeting dendritic cells, HIV and malarial vaccines outperform competitors

Although DNA-based vaccines are often in the limelight, scientists at Rockefeller University are developing a completely different approach to inducing immunity, one that directs a vaccine straight to the immune cells of living animals and, eventually, humans. More »

Tags: , , ,

Trial of new investigational AIDS vaccine begins in New York and Rochester

The Aaron Diamond AIDS Research Center (ADARC), an affiliate of The Rockefeller University, and the International AIDS Vaccine Initiative (IAVI) announced today that they have begun a human trial of a new investigational vaccine to prevent HIV/AIDS. The trial is actively seeking healthy volunteers in New York City and Rochester, New York. More »

Tags: , ,

No Viral Rebound After Stopping Drugs: An Anomalous Group of HIV Patients

An unusual group of HIV-infected patients who stopped taking antiviral drugs yet continued to suppress HIV replication may have somehow boosted their immune response against the virus by temporary therapy interruptions, researchers from the Aaron Diamond AIDS Research Center at Rockefeller University report. Although scientists strongly advise against halting drug therapy–because the virus usually comes surging back–this observation suggests that some HIV-infected people can suppress the virus without drugs if they have strong immune responses. More »

Tags: , ,

Rockefeller and Aaron Diamond Researchers Say Resistance to HIV Drugs May Be Higher Than Previously Thought

A study of patients infected with the AIDS virus revealed that about one in six was carrying a strain that is resistant to at least one of the drugs targeting HIV, researchers report from the Aaron Diamond AIDS Research Center, an affiliate of The Rockefeller University. Lead author Daniel Boden, M.D., and 11 colleagues report the research as the cover story in the Sept. 22-29 issue of the Journal of the American Medical Association. The authors suggest that further research should try to establish whether AIDS therapy structured around HIV-resistance testing would be more effective than current methods. More »

Tags: , ,